Dr. med.
Thomas Stübig
  • Medical specialist
  • Medical Specialist in Internal Medicine and Hematology and Oncology
  • Palliative Medicine
Working area

Contact

Location

O24
Languages
German (Mother tongue)
English

Areas of expertise

Publications

Zurück
  • 2024
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
Vor

67/m mit dekompensierter häuslicher Versorgung unter Erstlinientherapie beim metastasiertem kleinzelligem Bronchialkarzinom: Vorbereitung auf die Facharztprüfung: Fall 49
Oechsle K, Stübig T, Coym A, Schieferdecker A, Weidmann J
ONKOLOGIE-GER. 2024;30:886–890.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuketang F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kroger N
ACTA HAEMATOL-BASEL. 2015;134(3):146-154.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms
Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D
BRIT J HAEMATOL. 2015;169(6):824-33.

CD133 marks a stem cell population that drives human Primary Myelofibrosis
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N
HAEMATOLOGICA. 2015;100(6):768-79.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn J, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N
BIOL BLOOD MARROW TR. 2014;20(2):279-81.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuketang F, Reckhaus M, Blaise D, Kröger N
BIOL BLOOD MARROW TR. 2014;20(3):382-6.

Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation
Kröger N, Stübig T, Atanackovic D
BIOL BLOOD MARROW TR. 2014;20(2):168-72.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis
Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuketang F, von Huenerbein N, Kvasnicka H, Thiele J, Kreipe H, Büsche G
BIOL BLOOD MARROW TR. 2014;20(6):812-5.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuketang F, Kröger N
LEUKEMIA. 2014;28(8):1736-8.

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder T, Fehse B, Kröger N
MEDIAT INFLAMM. 2014;2014:418292.

Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis
Triviai I, Ziegler M, Bergholz U, Oler A, Stübig T, Prassolov V, Fehse B, Kozak C, Kröger N, Stocking C
P NATL ACAD SCI USA. 2014;111(23):8595 - 8600.

Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Derlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T, Habermann C, Adam G, Kröger N, Weber C
EUR RADIOL. 2013;23(2):570-8.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuketang F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander A
BIOL BLOOD MARROW TR. 2013;19(3):398-404.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger K, Burchert A, Stübig T, Wolschke C, Ayuketang F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander A
BONE MARROW TRANSPL. 2013;48(3):403-407.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N
EXP HEMATOL. 2013;41(2):133-134.

Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation.
Bannas P, Hentschel H, Bley T, Treszl A, Zu Eulenburg C, Derlin T, Yamamura J, Adam G, Stübig T, Kröger N, Weber C
EUR RADIOL. 2012;22(9):2007-2012.

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma.
Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stübig T, Sierich H, Badbaran A, Eiermann T, Binder T, Kröger N
Clin Dev Immunol. 2012;2012:652130.

Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.
Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuketang Ayuk F, Zander A, Kröger N
BONE MARROW TRANSPL. 2011;47(1):143-145.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjalle R, Ayuketang Ayuk F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-383.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hildebrandt Y, Atanackovic D, Alchalby H, Ayuketang Ayuk F, Zander A, Bacher U, Eiermann T
LEUKEMIA. 2011;25(10):1657-1661.

Letzte Aktualisierung aus dem FIS: 31.10.2024 - 03:43 Uhr